Overall, the frequencies of CCGTC in nonaggressive tumour groups were higher than that in comparatively aggressive tumour groups, although all of the differences didn't reach statistical significance (CCGTC in Her2 negative group vs. Her2 positive group = 8.37% vs. 6.64%; size≤2 cm group vs. size>2 cm group = 9.08% vs. 7.34%; negative lymph node metastasis group vs. positive lymph node metastasis group = 8.89% vs. 7.42%; clinical stage 0–I group vs. clinical stage II–IV group = 10.66% vs. 7.44%) (Table S5). This evidence concerns the gene ERBB2 and neoplasm.